Microglial Pro-Inflammatory and Anti-Inflammatory Phenotypes Are Modulated by Translocator Protein Activation.
Aminoglutethimide
/ pharmacology
Anti-Inflammatory Agents
/ pharmacology
Aromatase Inhibitors
/ pharmacology
Base Sequence
Cell Line
Cell Survival
/ drug effects
Cytokines
/ metabolism
Gene Expression
/ drug effects
Humans
Inflammation Mediators
/ metabolism
Microglia
/ drug effects
NF-kappa B
/ metabolism
Phenotype
Purines
/ pharmacology
RNA Interference
Receptors, GABA
/ genetics
human microglial cells
interleukins
neuroinflammation
neurosteroids
translocator protein 18 KDa
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Sep 2019
10 Sep 2019
Historique:
received:
10
07
2019
revised:
06
09
2019
accepted:
09
09
2019
entrez:
13
9
2019
pubmed:
13
9
2019
medline:
11
2
2020
Statut:
epublish
Résumé
A key role of the mitochondrial Translocator Protein 18 KDa (TSPO) in neuroinflammation has been recently proposed. However, little is known about TSPO-activated pathways underlying the modulation of reactive microglia. In the present work, the TSPO activation was explored in an in vitro human primary microglia model (immortalized C20 cells) under inflammatory stimulus. Two different approaches were used with the aim to (i) pharmacologically amplify or (ii) silence, by the lentiviral short hairpin RNA, the TSPO physiological function. In the TSPO pharmacological stimulation model, the synthetic steroidogenic selective ligand XBD-173 attenuated the activation of microglia. Indeed, it reduces and increases the release of pro-inflammatory and anti-inflammatory cytokines, respectively. Such ligand-induced effects were abolished when C20 cells were treated with the steroidogenesis inhibitor aminoglutethimide. This suggests a role for neurosteroids in modulating the interleukin production. The highly steroidogenic ligand XBD-173 attenuated the neuroinflammatory response more effectively than the poorly steroidogenic ones, which suggests that the observed modulation on the cytokine release may be influenced by the levels of produced neurosteroids. In the TSPO silencing model, the reduction of TSPO caused a more inflamed phenotype with respect to scrambled cells. Similarly, during the inflammatory response, the TSPO silencing increased and reduced the release of pro-inflammatory and anti-inflammatory cytokines, respectively. In conclusion, the obtained results are in favor of a homeostatic role for TSPO in the context of dynamic balance between anti-inflammatory and pro-inflammatory mediators in the human microglia-mediated inflammatory response. Interestingly, our preliminary results propose that the TSPO expression could be stimulated by NF-κB during activation of the inflammatory response.
Identifiants
pubmed: 31510070
pii: ijms20184467
doi: 10.3390/ijms20184467
pmc: PMC6770267
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Aromatase Inhibitors
0
Cytokines
0
Inflammation Mediators
0
N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide
0
NF-kappa B
0
Purines
0
Receptors, GABA
0
TSPO protein, human
0
Aminoglutethimide
0O54ZQ14I9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MIUR
ID : 2017MT3993
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Références
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20505-10
pubmed: 19075249
Front Cell Neurosci. 2018 Jul 24;12:215
pubmed: 30087595
Trends Neurosci. 2014 Mar;37(3):125-35
pubmed: 24388427
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
Glia. 2011 Feb;59(2):219-30
pubmed: 21125642
PLoS Pathog. 2017 Oct 27;13(10):e1006651
pubmed: 29077752
CNS Neurol Disord Drug Targets. 2016;15(2):242-9
pubmed: 26831265
J Steroid Biochem Mol Biol. 2015 Nov;154:68-74
pubmed: 26200949
Int J Mol Sci. 2017 Apr 07;18(4):
pubmed: 28387723
Glia. 2011 Jan;59(1):152-65
pubmed: 21046567
Adv Pharmacol. 2018;82:103-136
pubmed: 29413517
J Neurosci. 2014 Mar 5;34(10):3793-806
pubmed: 24599476
J Neuroendocrinol. 2018 Feb;30(2):
pubmed: 28667781
J Bioenerg Biomembr. 2008 Jun;40(3):199-205
pubmed: 18670869
J Neurochem. 2013 Oct;127(2):233-44
pubmed: 23895397
Cell Death Dis. 2017 Jun 22;8(6):e2896
pubmed: 28640253
J Neurosci Res. 2006 May 15;83(7):1293-8
pubmed: 16547968
Trends Pharmacol Sci. 2006 Aug;27(8):402-9
pubmed: 16822554
J Neuroinflammation. 2015 Nov 02;12:201
pubmed: 26527153
Biochem J. 2018 Mar 6;475(5):901-904
pubmed: 29511094
Int J Mol Sci. 2016 Jun 29;17(7):
pubmed: 27367681
ACS Chem Neurosci. 2012 Feb 15;3(2):114-9
pubmed: 22860181
Endocrinology. 1991 Sep;129(3):1481-8
pubmed: 1651852
Annu Rev Immunol. 2009;27:119-45
pubmed: 19302036
Nucleic Acids Res. 2003 Jul 1;31(13):3651-3
pubmed: 12824386
ChemMedChem. 2017 Aug 22;12(16):1275-1278
pubmed: 28467680
J Pharmacol Exp Ther. 2003 Sep;306(3):828-37
pubmed: 12928523
Contrast Media Mol Imaging. 2017 Sep 25;2017:6592139
pubmed: 29114179
Biochem Pharmacol. 2004 Jul 1;68(1):125-34
pubmed: 15183124
Bioinformatics. 2002 Feb;18(2):333-4
pubmed: 11847087
Curr Mol Med. 2012 May;12(4):426-42
pubmed: 22348611
Prog Neurobiol. 2015 Aug;131:65-86
pubmed: 26067058
Biochem Biophys Res Commun. 1999 Nov 19;265(2):457-61
pubmed: 10558889
Sci Rep. 2016 Jan 11;6:18164
pubmed: 26750656
Glia. 2007 Nov 1;55(14):1426-36
pubmed: 17674368
ACS Chem Neurosci. 2017 Jul 19;8(7):1448-1454
pubmed: 28362078
J Pharmacol Exp Ther. 2002 Jun;301(3):1067-78
pubmed: 12023539
Biochem Pharmacol. 2002 Jul 1;64(1):99-107
pubmed: 12106610
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
J Neuroinflammation. 2014 Jan 08;11:3
pubmed: 24397957
J Immunol. 1993 Apr 1;150(7):2659-67
pubmed: 8454848
J Neurochem. 2002 Nov;83(3):546-55
pubmed: 12390516
Biochim Biophys Acta. 2012 Jan;1819(1):38-56
pubmed: 21958735
Ann Transl Med. 2015 Jun;3(10):136
pubmed: 26207229
Front Aging Neurosci. 2017 Jun 08;9:176
pubmed: 28642697
J Neurosci Res. 2005 Apr 1;80(1):129-37
pubmed: 15696538
Br J Cancer. 1995 Feb;71(2):300-5
pubmed: 7841044
Br J Pharmacol. 2006 Jun;148(3):245-54
pubmed: 16604091
Psychoneuroendocrinology. 2019 Aug;106:65-76
pubmed: 30954920
J Neuroinflammation. 2018 Sep 10;15(1):259
pubmed: 30200996
DNA Cell Biol. 2017 Feb;36(2):103-108
pubmed: 28004979
Chembiochem. 2005 Jun;6(6):1082-8
pubmed: 15883977
Stroke Vasc Neurol. 2016 Jun 24;1(2):52-58
pubmed: 28959464
Free Radic Biol Med. 2014 Nov;76:34-46
pubmed: 25091898
J Neurovirol. 2017 Feb;23(1):47-66
pubmed: 27873219
J Mol Endocrinol. 2012 Oct 10;49(3):R125-34
pubmed: 22966132
Nat Med. 2017 Sep 8;23(9):1018-1027
pubmed: 28886007
J Neuroimmune Pharmacol. 2014 Jun;9(3):424-37
pubmed: 24687172
Neuropharmacology. 2003 Sep;45(3):293-303
pubmed: 12871647
J Exp Med. 2010 May 10;207(5):1067-80
pubmed: 20439540
PLoS One. 2018 Jul 26;13(7):e0200924
pubmed: 30048487
J Neuroimmune Pharmacol. 2013 Sep;8(4):807-23
pubmed: 23881706
ACS Chem Neurosci. 2016 Aug 17;7(8):1041-6
pubmed: 27385308
Blood Cells Mol Dis. 2000 Jun;26(3):211-22
pubmed: 10950941
Brain Res. 1999 Jan 2;815(1):70-80
pubmed: 9974124
Biotechniques. 1995 Oct;19(4):640-9
pubmed: 8777059
Cell Death Differ. 2001 Jul;8(7):747-53
pubmed: 11464219
Sci Rep. 2016 Jan 18;6:19371
pubmed: 26778406
Neurobiol Dis. 2005 Nov;20(2):550-61
pubmed: 15916899
Mol Cells. 2017 Mar;40(3):163-168
pubmed: 28301917
Retrovirology. 2017 Feb 6;14(1):9
pubmed: 28166799
J Immunol. 1998 Feb 15;160(4):1944-8
pubmed: 9469457
PLoS One. 2013 Oct 04;8(10):e76701
pubmed: 24124589
Int J Cancer. 2002 Dec 1;102(4):318-27
pubmed: 12402299
Eur J Pharm Sci. 2016 Jun 10;88:124-31
pubmed: 27094781
Blood. 1996 Apr 15;87(8):3170-8
pubmed: 8605331
J Cell Biochem. 2008 Oct 15;105(3):712-23
pubmed: 18668527
PLoS One. 2018 May 10;13(5):e0196541
pubmed: 29746502